Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1459 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: PsA is a chronic inflammatory disease characterized by joint pain, swelling and stiffness, and is often accompanied by cutaneous changes linked to psoriasis. Patients…
Abstract Number: 1911 • ACR Convergence 2025
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
Victoria Konzett¹, Eva Manger², Simon Reider², Johannes Griss³, Constanze Jonak³, Kastriot Kastrati⁴, Peter Mandl⁴, Gudrun Ratzinger⁵, Christina Duftner², Thomas Karonitsch⁴ and Daniel Aletaha⁶, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, ³Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Medical University Vienna, Wien, Austria
Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
Abstract Number: 2321 • ACR Convergence 2025
Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
Martín Valdez-López¹, Ana Barrera-Vargas¹, Javier Merayo-Chalico², Irazú Contreras-Yañez³, Carlos Abdiel Abitia Borboa⁴, Iris Paola García-Herrera¹, Raúl Pérez-Gamboa¹ and Guillermo Arturo Guaracha-Basáñez¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Distrito Federal, Mexico, ²Reumátika, Centro de Vanguardia en Reumatología, Ciudad de México, Federal District, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Mexico, ⁴Universidad Autónoma de Sinaloa Facultad de Medicina Culiacán, Culiacan, Sinaloa, Mexico
Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…
Abstract Number: 2362 • ACR Convergence 2025
Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Mauro Keiserman¹, Kim Papp², Douglas White³, Angela Crowley⁴, Joseph F Merola⁵, Hayley Barnard⁶, Ana Biljan⁷, Thomas Iyile⁸, Lingfeng luo⁶, Douglas Ashley⁶, Arathi Setty⁸, Hayato Yamazaki⁶ and Frank Behrens⁹, ¹Rheumatology Section, Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil, ²Probity Medical Research and Alliance Clinical Trials, Waterloo, and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Rheumatology Department, Waikato Hospital, Hamilton, New Zealand, ⁴Willow Rheumatology and Wellness, Willowbrook, IL, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., Buffalo Grove, IL, ⁸AbbVie Inc, North Chicago, IL, ⁹Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, is approved for the treatment of adults with active PsA. We report the efficacy and safety of…
Abstract Number: 2613 • ACR Convergence 2025
Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
Giulia Corte¹, Koray Tascilar², armin Atzinger³, Alp Temiz², Melek Yalcin Mutlu⁴, Rita Noversa de Sousa⁵, Maria Gabriella Raimondo⁶, Andreas Ramming⁷, Sara Bayat², Michael Sticherling⁸, Torsten Kuwert⁹, Christian Schmidkonz⁹, Georg Schett¹⁰ and Filippo Fagni¹¹, ¹- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, erlangen, ⁵Department of Internal Medicine ³, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, ⁶Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Dermatology, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany
Background/Purpose: 68Ga-FAPI-04 PET/CT reveals fibroblast activation in vivo and is increasingly used to assess rheumatic diseases, including inflammatory arthritides. (1,2) We previously demonstrated that the…
Abstract Number: 0107 • ACR Convergence 2025
Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
IRENE MARTIN MARTIN¹, CARMEN SAN JOSE MENDEZ², SONIA JIMENEZ BARRIOS³, ELENA MARTIN FERNANDEZ⁴, JULIA MIRANDA MANZANO⁵, DIEGO DIOS SANTOS⁶, JORGE GONZALEZ MARTIN⁷, PABLO ZURITA PRADA⁷, MONICA VAZQUEZ DIAZ⁸ and CARLOS GUILLEN-ASTETE⁹, ¹HOSPITAL VIRGEN DE LAS NIEVES, GRANADA, ²Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴HOSPITAL UNIVERSITARIO RAMON Y CAJAL, MADRID, ⁵FACULTAD BIOMEDICINA, MADRID, ⁶HOSPITAL DE VERÍN, OURENSE, ⁷HOSPITAL UNIVERSITARIO HM SANCHINARRO, MADRID, ⁸HOSPITAL UNIVERSITARIO HLA MONCLOA, MADRID, ⁹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: Elastography (EL) is an imaging technique that evaluates the biomechanical properties of tissues. Pathological tissues have different elastic properties compared to healthy tissues.In diseases…
Abstract Number: 0522 • ACR Convergence 2025
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
Abdulrahman Y Almansouri¹, Jiayi Li², Ali Alhadri³, Keith Colaco⁴, Paula Harvey⁵, Shadi Ahktari⁶, Vinod Chandran⁷, Dafna D. Gladman⁸, Richard Cook² and Lihi Eder⁷, ¹King Faisal Specialist Hospital and Research Centre, University of Toronto and Women's College Hospital, Toronto, Canada, ²University of Waterloo, Waterloo, Canada, ³King Fahad Hospital, University of Toronto and Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of developing cardiovascular diseases, including arrhythmias. Given that traditional cardiovascular disease risk factors are prevalent…
Abstract Number: 0877 • ACR Convergence 2025
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Rodrigo García Salinas¹, Gisel Reyes-Jara², Felicia Almada³, Juan Arguello² and Sebastian Magri⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano de La Plata, La Plara, Argentina, ⁴Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The transition from psoriasis (Pso) to psoriatic arthritis (PsA) presents an opportunity for early intervention and preventive strategies in high-risk patients with arthralgia. Objectives:…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Francisco Arias¹, Omar Hamdan², Asim Khanfar³, Kristel Barturen⁴ and Roa’a Alshajrawi⁵, ¹University of Texas Rio Grande Valley, McAllen, TX, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Rochester, NY, ⁴Universidad San Martin de Porres, McAllen, TX, ⁵University of Jordan, Amman, 'Amman, Jordan
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…
Abstract Number: 1427 • ACR Convergence 2025
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Ricardo I. De la Rosa-Vazquez⁵, Victoria P. Limas-Martínez⁵, Annette Dominguez-Guerra⁵, Jesus Alberto Cardenas-de la Garza⁶, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁷, Victor M Fraga-Enriquez⁸ and Diego Azamat Salcedo Almanza⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁸Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁹Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk due to a higher prevalence of comorbidities and chronic systemic inflammation. In those…
Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert¹, Mohamed Sharaf², Frank Behrens³, Proton Rahman⁴, mitsumasa kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Ruben Queiro¹⁰, Ennio Lubrano¹¹ and Laure Gossec¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ¹¹Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
Abstract Number: 1945 • ACR Convergence 2025
Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
Victoria Furer¹, iris Eshed², Moshe Iluz¹, Ori Elkayam³ and Ari Polachek⁴, ¹Tel-Aviv Medical Center, Tel-Aviv, Israel, ²Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer affiliated with School of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Tel Aviv medical center, Tel Aviv, Israel, ⁴Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel
Background/Purpose: Musculoskeletal involvement in psoriatic arthritis (PsA) affects both articular and extra-articular structures, presenting as inflammatory and structural lesions. The relationship between tender and/or swollen…
Abstract Number: 2323 • ACR Convergence 2025
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
Mitndbaim Parra¹, Marta Flores², María Ángeles Puche-Larrubia³, Alejandro Escudero Contreras⁴, María Dolores López-Montilla⁵ and Clementina López Medina⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…
Abstract Number: 2363 • ACR Convergence 2025
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Milad Heydari-Kamjani¹, Jennifer Murphy² and Marina Magrey³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), yet the comparative safety of…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].